Regimen Reference Order – GAST – PANitumumab

ARIA: GAST - [PANitumumab]

Planned Course: Every 14 days until disease progression or unacceptable toxicity

Indication for Use: Colorectal Cancer Metastatic

CVAD: At Provider's Discretion

Proceed with treatment if:

ANC equal to or greater than 1.5 x $10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$

Contact Physician if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements				
Drug	Dose	CCMB Administration Guideline		
Not Applicable				

Establish primary solution 500 mL of: normal saline			
Drug	Dose	CCMB Administration Guideline	
PANitumumab	6 mg/kg	IV in normal saline 100 mL over 1 hour	
		If Cycle 1 of PANitumumab is tolerated, the subsequent infusions may be administered over 30 minutes	
		Doses greater than 1000 mg must be administered over 90 minutes	
		Use 0.2 or 0.22 micron filter	

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

All Cycles

- CBC, biochemistry and magnesium as per Physician Orders
- Clinical toxicity assessment prior to each cycle (including dermatological, gastrointestinal, pulmonary and ophthalmic assessment)
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated



ADULT GAST – PANitumumab

Recommended Support Medications			
Drug	Dose	CCMB Administration Guideline	
doxycycline	100 mg	Orally twice daily for 14 days. Repeat with each cycle	
hydrocortisone cream	1%	Apply topically daily at bedtime to face, hands, feet, neck, back and chest as directed	
Moisturizing lotion	Fragrance-free	Apply topically to face, hands, feet, neck, back and chest daily in the morning on rising and <u>as needed</u>	
Sunscreen	Broad-spectrum, Minimum SPF 15 (PABA free, zinc oxide or titanium dioxide preferred)	Apply liberally to exposed skin 30 minutes before going outdoors. Reapply every 2 hours and after swimming	

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Instruct patient to use recommended support medications at home

ADDITIONAL INFORMATION

• Not applicable

